Armis vs Claroty
The two platform giants in healthcare device security share a structure, healthcare capability inside a broader industrial platform, and differ on validation and future ownership. Claroty's healthcare product is Medigate, acquired in 2022 and purpose built for hospital networks: passive deep packet inspection across a reported 500 plus device protocols with clinical context in its threat detection, protecting a reported 20 million plus devices across 2,000 plus hospital facilities, and named Best in KLAS for Healthcare IoT Security multiple years, a healthcare specific buyer signal. Armis validates cross industry: a Leader in the 2026 Gartner Magic Quadrant for CPS Protection Platforms for the second consecutive year, with a unified risk model correlating device context, anomalies, vulnerabilities, and exposure pathways, and deployment flexibility across on premise, cloud, and hybrid. One forward looking fact belongs in the verdict: Armis has announced a planned acquisition by ServiceNow expected to complete in the second half of 2026, so buyers signing multi year agreements are contracting with a company changing owners. If your failure mode is clinical device depth judged by hospital buyers, start with Claroty. If your failure mode is one exposure model across hospital, campus, and industrial estate, start with Armis, and put contractual continuity in the negotiation.
- One risk model across the whole estate: device context, behavioural anomalies, vulnerability intelligence, and exposure pathways correlated into unified prioritisation, spanning hospital, OT, IoT, and enterprise assets.
- Cross industry analyst validation: a Leader in the 2026 Gartner Magic Quadrant for CPS Protection Platforms for the second consecutive year, with 119 Peer Insights reviews rating 4.7 of 5 as of March 2026.
- Deployment flexibility is your constraint: on premise, cloud, and hybrid options, graded A on this index's deployment axis.
- Clinical device depth judged by hospital buyers: Best in KLAS for Healthcare IoT Security multiple years, a healthcare specific survey signal, on a platform protecting a reported 20 million plus devices across 2,000 plus hospital facilities.
- Protocol coverage where fragile devices live: passive deep packet inspection with light active techniques across a reported 500 plus device protocols, and an anomaly module that adds clinical context to prioritise threats.
- Ownership stability by comparison: Claroty completed its healthcare acquisition in 2022 and has operated Medigate since, while Armis's pending ServiceNow acquisition leaves integration questions open through at least late 2026.
Side-by-Side
| Axis | A Armis |
C Claroty |
|---|---|---|
| AI Centrality | ||
| Autonomy and Oversight Model | — | |
| Model and Technology Transparency | — | |
| Clinical and Operational Evidence | ||
| AI Safety and PHI Stewardship | — | |
| HIPAA and BAA Posture | — | |
| Security Certifications and Trust Center | — | |
| FDA and Regulatory Status | — | |
| AI Governance and Bias Disclosure | — | |
| EHR and Interoperability Depth | — | |
| Deployment Model and Data Residency | ||
| Commercial Transparency | ||
| Setting and Specialty Coverage |
Device and facility counts for both vendors are vendor published. Both companies are horizontal platforms whose healthcare capability sits inside a broader industrial security business, and independent Gartner Peer Insights commentary on Armis notes that while asset visibility is strong, some users find OT and CPS protocol depth less than top tier. Armis's planned acquisition by ServiceNow, expected to complete in the second half of 2026, is a forward looking announcement rather than a settled outcome. Neither vendor publishes pricing, consistent with this index's lane wide finding that none of its indexed healthcare cybersecurity vendors publishes a security attestation.